Ixekizumab is a monoclonal antibody targeting interleukin-17 approved for the treatment of psoriasis. In a recent post hoc meta-analysis of Phase-I to Phase-III clinical trials of anti-interleukin-17 agents for the treatment of plaque psoriasis, there was a rare association (<1%) with induction or exacerbation of inflammatory bowel disease. We report a case of new-onset ileal Crohn's disease in a 48-year-old woman on ixekizumab for psoriasis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209798 | PMC |
| http://dx.doi.org/10.14309/crj.0000000000000316 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IL-17 and IL-23 inhibitors have shown successful results in improving skin lesions in the treatment of moderate-to-severe plaque psoriasis. However, psoriasis is a chronic inflammatory disease characterized by systemic inflammation including joints in addition to skin lesions. Therefore, in this retrospective and observational cohort study, we aimed to evaluate the effect of IL-17 inhibitors (secukinumab and ixekizumab) and IL-23 inhibitors (risankizumab and guselkumab) on systemic inflammation in psoriasis.
View Article and Find Full Text PDFObesity is a metabolic disease that is marked by excessive fat accumulation and is objectively defined as a body mass index (BMI) ≥30 kg/m2. Obesity is associated with several other comorbidities, including psoriasis, which is a chronic autoimmune skin disease. Adipocytes produce pro-inflammatory signaling molecules, namely adipokines and classic cytokines, that drive increased inflammation axnd may contribute to the pro-inflammatory pathways driving psoriasis disease pathogenesis.
View Article and Find Full Text PDFIxekizumab-Associated Generalized Vitiligo and Pruritus in a Psoriatic Patient.
Indian J Dermatol
October 2024
From the Department of Dermatology, College of Medicine, Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, South Korea E-mail:
Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study.
Int Arch Allergy Immunol
December 2024
Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
Article Synopsis
- The study investigates the safety of various biologics used for psoriasis during pregnancy, highlighting that data on risks is lacking outside of TNF-α inhibitors.
- Using the WHO global pharmacovigilance database, researchers analyzed over 6,500 reports of pregnancy-related adverse outcomes and compared them among different biologics.
- The findings indicate that most biologics have a lower frequency of adverse pregnancy-related outcomes compared to TNF-α inhibitors, except for brodalumab, while risankizumab showed a higher incidence of abortion and stillbirth.
Risk of Malignancy Related to Ixekizumab in Patients in Patients With Psoriatic Arthritis or Axial Spondyloarthropathy: Systematic Review and Meta-analysis.
J Clin Rheumatol
December 2024
Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, Medical School, Universidad de Santiago de Compostela.
Article Synopsis
- The study evaluated the malignancy risk linked to ixekizumab in patients with rheumatological conditions through a systematic review of randomized controlled trials (RCTs) and long-term extension studies (LTEs).
- Meta-analyses indicated a low overall risk of malignancy, with Peto odds ratios showing varied results when compared to placebo and another drug, adalimumab.
- The research concluded that while ixekizumab generally poses a low risk for malignancy, certain conditions, like nonmelanoma skin cancer, may be exceptions for patients with psoriatic arthritis and axial spondyloarthritis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!